Company news

AC Immune SA news in 2023

AC Immune SA's news releases, calls and decks from 2023, newest first.

View company

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial

December 14, 2023

AC Immune Announces Pricing of Underwritten Offering of Common Shares

December 14, 2023

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

November 30, 2023

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

November 6, 2023

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

November 2, 2023

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023

November 1, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

October 26, 2023

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

October 16, 2023

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

October 4, 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

September 4, 2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

August 3, 2023

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

July 27, 2023

AC Immune SA Appoints New Chief Medical Officer

July 25, 2023

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

July 2, 2023

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s Disease

June 26, 2023

AC Immune Holds Annual General Meeting of Shareholders

June 22, 2023

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

April 27, 2023

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease

April 4, 2023

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

March 19, 2023

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

March 15, 2023

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

March 7, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

February 6, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

January 25, 2023

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

January 17, 2023

Decks in 2023